HC Wainwright Has Bearish Estimate for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.97) per share for the quarter, down from their prior forecast of ($0.93). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.71) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. During the same period last year, the company posted ($1.27) earnings per share. Intellia Therapeutics’s revenue was up 78.4% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on the company. Citizens Jmp increased their price target on Intellia Therapeutics from $21.00 to $28.00 and gave the company a “market outperform” rating in a research note on Tuesday. Truist Financial restated a “buy” rating and set a $14.00 price objective (down from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a research report on Friday, November 7th. JonesTrading downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Royal Bank Of Canada raised their price target on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.14.

Intellia Therapeutics Stock Down 11.9%

Shares of Intellia Therapeutics stock opened at $13.60 on Wednesday. The company has a market cap of $1.61 billion, a P/E ratio of -3.55 and a beta of 2.10. The firm’s 50 day moving average price is $12.09 and its 200-day moving average price is $13.10. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Comerica Bank lifted its holdings in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. Headlands Technologies LLC purchased a new position in Intellia Therapeutics during the second quarter valued at approximately $26,000. Blue Bell Private Wealth Management LLC acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $30,000. Finally, Advisory Services Network LLC purchased a new stake in Intellia Therapeutics in the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James Basta sold 10,397 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. The trade was a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.